Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Lung Non-Small Cell Squamous Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non Small Cell Lung Cancer (3690
)
Lung Adenocarcinoma (656
)
Lung Non-Squamous Non-Small Cell Cancer (163
)
Non Small Cell Lung Cancer (3690
)
Lung Adenocarcinoma (656
)
Lung Non-Squamous Non-Small Cell Cancer (163
)
›
Associations
(111)
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR expression
Lung Non-Small Cell Squamous Cancer
EGFR expression
Lung Non-Small Cell Squamous Cancer
necitumumab
Sensitive: A1 - Approval
necitumumab
Sensitive
:
A1
necitumumab
Sensitive: A1 - Approval
necitumumab
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
sintilimab
Sensitive: A1 - Approval
sintilimab
Sensitive
:
A1
sintilimab
Sensitive: A1 - Approval
sintilimab
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
serplulimab
Sensitive: A1 - Approval
serplulimab
Sensitive
:
A1
serplulimab
Sensitive: A1 - Approval
serplulimab
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
penpulimab
Sensitive: A1 - Approval
penpulimab
Sensitive
:
A1
penpulimab
Sensitive: A1 - Approval
penpulimab
Sensitive
:
A1
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
bevacizumab
Resistant: A2 - Guideline
bevacizumab
Resistant
:
A2
bevacizumab
Resistant: A2 - Guideline
bevacizumab
Resistant
:
A2
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
paclitaxel
Sensitive: A2 - Guideline
paclitaxel
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
docetaxel
Sensitive: A2 - Guideline
docetaxel
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
carboplatin + albumin-bound paclitaxel
Sensitive
:
A2
carboplatin + albumin-bound paclitaxel
Sensitive: A2 - Guideline
carboplatin + albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
albumin-bound paclitaxel
Sensitive: A2 - Guideline
albumin-bound paclitaxel
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
EP
Sensitive: A2 - Guideline
EP
Sensitive
:
A2
EP
Sensitive: A2 - Guideline
EP
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
GC
Sensitive: A2 - Guideline
GC
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
CP
Sensitive: A2 - Guideline
CP
Sensitive
:
A2
CP
Sensitive: A2 - Guideline
CP
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
GD
Sensitive: A2 - Guideline
GD
Sensitive
:
A2
GD
Sensitive: A2 - Guideline
GD
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
PD-L1 overexpression
Lung Non-Small Cell Squamous Cancer
cemiplimab-rwlc
Sensitive: A2 - Guideline
cemiplimab-rwlc
Sensitive
:
A2
cemiplimab-rwlc
Sensitive: A2 - Guideline
cemiplimab-rwlc
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
carboplatin + docetaxel
Sensitive: A2 - Guideline
carboplatin + docetaxel
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
GemVin
Sensitive: A2 - Guideline
GemVin
Sensitive
:
A2
GemVin
Sensitive: A2 - Guideline
GemVin
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
ramucirumab
Sensitive: A2 - Guideline
ramucirumab
Sensitive
:
A2
ramucirumab
Sensitive: A2 - Guideline
ramucirumab
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
atezolizumab
Sensitive: A2 - Guideline
atezolizumab
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
VC
Sensitive: A2 - Guideline
VC
Sensitive
:
A2
VC
Sensitive: A2 - Guideline
VC
Sensitive
:
A2
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
GemCarbo
Sensitive: A2 - Guideline
GemCarbo
Sensitive
:
A2
GemCarbo
Sensitive: A2 - Guideline
GemCarbo
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login